Leading researchers gathered in Long Beach, California, for the 16th annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), which took place from February 19 through 22. nPOD is now the world’s largest tissue bank dedicated to the study of the human pancreas in type 1 diabetes (T1D), and researchers, clinicians, people with T1D, and other leaders in the diabetes space attended—more than 200—to hear results from the latest advances using nPOD samples.
Here are some of the highlights:
- Breakthrough T1D staff Esther Latres, Ph.D., vice president of research at Breakthrough T1D, and Josh Vieth, Ph.D., director of research focusing on disease-modifying therapies, co-chaired a session on the cellular mechanisms in and around T1D:
-
- Breakthrough T1D-funded Tim Tree, Ph.D., presented on islet-specific immune responses, with the goal of developing a tool to measure them in clinical trials. He discovered that islet-specific immune cells have distinct characteristics and pointed to the potential for correlation of immune cell characteristics with (i) age of onset, (ii) clinical progression, and (iii) genetic protection.
-
- Melanie Shapiro, Ph.D., who has a Breakthrough T1D postdoctoral fellowship, identified an immune cell receptor pattern in blood moving throughout the circulatory system (as opposed to blood in a specific organ, like the pancreas) that was augmented in T1D, compared to blood that was non-T1D. This pattern was used to run multiple analyses, and all of the associations showed increased frequency of this pattern and gene mutations for T1D.
-
- Carla Di Dedda, Ph.D., presented on her Breakthrough T1D grant on the glucose transporter GLUT1. Seven to eight percent of pancreas transplant recipients have a recurrence of T1D without rejection of their organ donation, and Dr. Di Dedda focused on GLUT1 as a culprit. She found that in people with T1D, immune cell proliferation was significantly reduced when GLUT1 was blocked, which will be instrumental in future research on the roles of GLUT1 in T1D.
- Miguel Medina-Serpas, who is a graduate student with Todd Brusko, Ph.D.—who received early-career scientist grants from 2008 through 2017 from Breakthrough T1D and three grants since—presented on visual-spatial gene expression on paired pancreas and lymph node slices. He found that it could reliably identify functional compartments of the pancreas. This could help to validate gene targets for therapeutic use.
- Esra Karakose, Ph.D., from the laboratory of Andrew Stewart, Ph.D., at the Icahn School of Medicine at Mount Sinai, focused on the action of beta cell regenerative drugs and which subtypes are responsible for treatment. Her lab found that the most responsive is the cycling alpha cell, which cluster between alpha and beta cells. She explained that cycling alpha cells become “beta-like cells” in response to treatment with the drugs DMSO and harmine, which may restore the beta cells that are lost in people with T1D.
Since being established in 2007 with a $7 million grant from Breakthrough T1D, nPOD has collected and processed more than 50,000 tissue samples from organ donors who had or were at increased risk for T1D. nPOD is conducting more than 250 studies to unlock the mysteries of the human pancreas. For more information on nPOD, you can visit their website here.
You are helping us advance toward preventing, treating, and—one day—curing T1D. Find out more about Breakthrough T1D here.
Leading researchers from around the world will gather for the 16th annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), taking place from February 19-22 in Long Beach, California. The latest advances—using nPOD samples—will be discussed, including:
- Enhanced T Cell Receptors: There are several presentations on T cell receptors (TCRs)—which recognize a foreign substance and cause the T cell to attack—to restore immune tolerance in T1D. Immunocore, a company with an investment from the Breakthrough T1D T1D Fund, will present on ImmTAAI, a TCR that binds to the beta cell with an antibody that down-regulates the immune system. Also with support from the T1D Fund is Abata Therapeutics, which will present on their TCR that will restore immune tolerance by bringing regulatory T cells to the islet cells and promote immune suppression.
Since it was established in 2007 with a $7 million grant from Breakthrough T1D, nPOD has collected and processed more than 50,000 tissue samples from organ donors who had or were at increased risk for type 1 diabetes, and has provided, without cost, these tissues to researchers around the world.
- Change the Current Staging Model: In a Breakthrough T1D-support-bonanza, going back to 1992 with a postdoctoral fellowship to Alberto Pugliese, M.D.—who is now the co-director of nPOD—we will hear from several investigators who will debate on when T1D begins and whether we should modify the current staging model. The current staging model has three parts: Stage 1 is the presence of 2+ autoantibodies—antibodies against one’s own body—but blood sugar is normal; Stage 2 is 2+ autoantibodies and the blood sugar is abnormal; Stage 3 is the onset of clinical symptoms. We can’t wait to hear the outcome of this discussion!
- Clinical Trials: Breakthrough T1D staff Esther Latres, Ph.D., vice president of research at Breakthrough T1D, and Josh Vieth, Ph.D., director of research focusing on disease-modifying therapies, are co-chairing a session on clinical trials. Breakthrough T1D-funded Tim Tree, Ph.D., will present on a test to determine islet-specific T cells; Melanie Shapiro, Ph.D., who has a Breakthrough T1D postdoctoral fellowship, will discuss immune risk and changes to the TCR repertoire; Carla Di Dedda, Ph.D., will present on her Breakthrough T1D grant on the glucose transporter GLUT1; and Guido Sebastiani, Ph.D., will discuss microRNAs—which play an important role in regulating gene expression—associated with T1D.
Keep up with the latest updates and exciting news from the nPOD annual meeting on Facebook (@BreakthroughT1DHQ), X (formerly Twitter) (@BreakthroughT1D), and LinkedIn.
Editor’s note: Written by guest blogger, Grace Bennett, Social Media Manager at Breakthrough T1D. The opinions expressed by the author are her own and are not necessarily those of JDRF, its leadership, employees, or supporters.
Life with T1D means you don’t only observe your birthday, holidays, and anniversaries. You also usually in some way mark your “Diaversary” or the day your life with T1D began.
I’ve always felt a bit conflicted about my Diaversary. While I feel like I should do something to recognize a day that completely changed my life, it’s obviously not something I necessarily want to celebrate.
Who in their right mind would celebrate being diagnosed with a condition that adds significantly to one’s mental load (and that’s just the tip of the iceberg!)?
I tend to quietly acknowledge my Diaversary with my family and then move on. That changed a few weeks ago, when I realized that life with type 1 diabetes (T1D) has taught me a lot of life lessons that I might not have learned otherwise. So, here are the 19 things I’ve learned over the 19+ years I’ve lived with T1D.
- Pretending something isn’t happening is not going to make it go away. This was my approach to T1D management during my teenage years, 0/10 recommend. Also, sorry mom and dad!
- If you overpack extra supplies, you likely won’t need them. You know when you will? The one time you try to “pack light.”
- Most of the time, people who suggest homeopathic “cures” like cinnamon for your T1D mean well, even though they are misguided. Using these moments as an opportunity to educate instead of getting defensive will feel a lot better than jumping down someone’s throat.
- Just because your illness is largely invisible doesn’t mean it’s easy. You’ll hear a lot of “at least it’s T1D and not *insert scarier illness here*” but the truth is, no one “wins” in a contest of who has it worse. Any illness or health condition is difficult in its own way.
- I really do not care if people see my T1D tech. I promise when you look back on photos from your eighth grade dance, the tubing from your insulin pump being visible won’t be one of things you cringe at.
- Pack the number of low treatments you think you’ll need and then double it. You’ll thank me later.
- Don’t get caught up in comparison to other people living with T1D who seem to be doing better than you are. This is the furthest thing from a “one size fits all” disease.
- Your blood sugar will get low at the MOST inconvenient times.
- Find community, whether it’s in-person or online. JDRF’s CEO, Dr. Aaron Kowalski says frequently that the T1D community is “the best club you never want to be a part of” and he is spot on.
- Don’t beat yourself up if you’re having a bad blood sugar day, especially an inexplicable one.
- Speaking of, don’t forget that more than just carbohydrates and exercise impact blood sugar. Stress, having a cold or the flu, hormonal changes, and any other number of variables can also throw your HbA1c off kilter.
- Don’t be afraid to advocate for yourself and ask questions at your medical appointments. If something doesn’t feel or seem right to you, mention it!
- Don’t fall into the trap of defining your whole life as “good T1D days” and “bad T1D days.” If you tried your best, even if your blood sugar wasn’t exactly where you wanted it to be, remember your best is enough.
- The field of T1D research IS progressing faster than ever before in the most exciting ways. Working at Breakthrough T1D and getting to see not just the big milestones, but also the small pieces of progress being made is something that’s been an eye opener.
- Your friends and family who don’t live with T1D won’t ever fully understand how it feels, but that doesn’t mean they don’t want to. Try your best to keep that in mind.
- It’s in no way, shape, or form your fault that your body doesn’t do something it’s supposed to.
- There really is no such thing as a stupid question when it comes to T1D—if you aren’t sure about something, ask!
- T1D burnout is real and can look different for everyone. If you find yourself struggling, I promise that asking for help will make you feel a massive wave of relief.
- Feel your feelings; resentment, anger, frustration, joy, sadness, etc., are all part of life with T1D. There is no wrong way to feel about life with a chronic illness.
As Breakthrough T1D’s Social Media Manager, I can confidently say that the T1D community has a tremendous amount of wisdom about life with T1D to share beyond the points I’ve listed here. Don’t forget to go check out the comments on our Social Media channels for more advice from this incredible group of folks!
Leading diabetes researchers gathered for the annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), which took place from October 18-21 in Rotterdam, The Netherlands, and had more than 1,600 attendees—its largest-ever audience.
More than 45 studies were presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the condition today. Here are some of the highlights:
- Presented by Kevan Herold, M.D., and published in the New England Journal of Medicine, the phase III PROTECT clinical trial investigated whether Tzield™ (teplizumab-mzwv) can slow the loss of beta cells and preserve beta cell function in newly diagnosed (stage 3 T1D) children and adolescents ages 8-17. Per the study results, it can. Participants treated with Tzield had:
- Significantly greater stimulated C-peptide levels (a measure for insulin secretion) compared with placebo
- Tended to use lower insulin doses to meet glycemic goals
- Experienced higher rates of predefined clinical remission, defined as participants who achieved HbA1c ≤6.5% and insulin daily dose ≤0.25 U/kg/day
- Conclusion: Tzield has the potential to slow the progression of Stage 3 T1D and improve clinical parameters in newly diagnosed individuals.
Dr. Herold has been supported by Breakthrough T1D since the late 1980s. In his research, he showed that he could prevent autoimmune diabetes with an immune-modifying antibody (which, later, became a humanized version, Tzield) and was the lead on the clinical trial that demonstrated that Tzield could delay the onset of T1D in people almost certain to develop the disease. In November 2022, Tzield was approved by the FDA to delay the onset of the disease (Stage 3) in at-risk (Stage 2) individuals ages 8+.
- In a joint ISPAD-Breakthrough T1D symposium about global pediatric diabetes development, we heard from Tom Robinson, who heads the T1D Index. The Index leverages machine learning models to estimate the incidence of T1D around the globe. According to the Index, in access to care and quality of life most significantly affect low- and middle-income countries. Robinson pointed to four key areas of intervention to address the global T1D crisis, which ISPAD and Breakthrough T1D are working to address:
- Manuela Battaglia, Ph.D., discussed impediments in the T1D therapy research and development pipeline and how INNODIA—an international public-private partnership, with Breakthrough T1D and others support—is addressing the problem. Established in 2015, INNODIA was launched to accelerate the development of new disease-modifying therapies for T1D by fostering the creation of centers of excellence and by building a global network of members and experts. INNODIA now has four intervention clinical trials, paving the way for the development of novel treatments to prevent and find cures for T1D.
- In the complications space, Farid Mahmud, M.D., a Breakthrough T1D grantee since 2017, presented on the need for better blood biomarkers to earlier identify diabetic kidney disease. In his Breakthrough T1D-funded ATTEMPT clinical trial, which examines the impact of SGLT2 inhibitors (such as Jardiance®) on adolescents and young adults with T1D, he is investigating whether decreasing how much glucose is absorbed by the kidney is beneficial in diabetes-related complications. The study has already enrolled 98 out of 100 participants and is set to complete in mid-2024.
The next conferences we’ll be covering are the:
- Network for Pancreatic Organ Donors with Diabetes (nPOD), from February 19-22, 2024, in Long Beach, California
- Advanced Technologies & Treatments for Diabetes (ATTD), from March 6-9, 2024, in Florence, Italy (and online)
Stay tuned for a precap and recap of these terrific meetings!
Leading researchers from around the world will gather for the annual meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD). At this year’s meeting, which will take place from October 18-21 in Rotterdam, The Netherlands, more than 45 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the condition today. Let’s have a look:
- The first findings from the PROTECT clinical trial, which tested the disease-modifying therapy Tzield™ (teplizumab-mzwv) in children with new-onset T1D. The findings are being presented by Kevan Herold, M.D.— who Breakthrough T1D has supported since the late 1980s. In his research, Dr. Herold showed that he could prevent autoimmune diabetes with an immune-modifying antibody (which, later, became a humanized version, Tzield) and was the lead on the clinical trial that demonstrated that Tzield could delay the onset of T1D in people almost certain to develop the disease. In November 2022, Tzield was approved by the FDA to delay the onset of the disease in at-risk individuals.
- In a joint ISPAD-Breakthrough T1D symposium on global pediatric diabetes development, we will hear from Tom Robinson, who heads the T1D Index, the first-of-its-kind tool that provides the most accurate and comprehensive picture of how many people live with T1D in every country in the world. Joining Tom will be Graham Ogle, MBBS, FRACP, who will discuss the Life for a Child Program, an international aid program that provides life-saving support to children and youth with diabetes in developing countries.
- In a presentation by Line Wisting, Ph.D., we will get an update on the Breakthrough T1D-funded clinical trial testing a virtual eating disorder prevention program for young women with type 1. They have recruited approximately three-quarters of their planned 240, and we will get results on the first 6 months of the study. About two-thirds of young women with T1D develop eating disorders in their lifetimes, so this is a very important and timely topic.
- In a symposium sponsored by Sanofi, we will hear from Breakthrough T1D chief scientific officer Sanjoy Dutta, Ph.D., Thomas Danne, M.D.—who were both Breakthrough T1D postdoctoral fellows when they were at the Joslin Diabetes Center—and Kimber Simmons, M.D., M.S., as they discuss general population screening for T1D and how we can work together to help individuals and their families prepare for and potentially delay this chronic health condition.
Keep up with the latest updates and exciting news from the ISPAD annual conference on Facebook (@myJDRF), X (formerly Twitter) (@JDRF), and LinkedIn, with the hashtags #JDRFxISPAD and #ISPAD2023.
Leading researchers gathered in Hamburg, Germany, for the annual meeting of the European Association for the Study of Diabetes (EASD), which took place from October 2-6. Researchers, clinicians, and other leaders in the diabetes space from more than 120 countries attended—including experts from Breakthrough T1D and the Breakthrough T1D T1D Fund. The meeting featured more than 65 studies presented by Breakthrough T1D-funded researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today.
Research presented at this conference covered all areas of Breakthrough T1D’s research portfolio, from disease-modifying therapies to cell therapies to complications. Here are some of the highlights:
- Anti-Viral Drugs Against Enteroviruses: The first findings from the Breakthrough T1D-funded clinical trial (DiViD) to test two anti-viral drugs against enteroviruses—common viruses that cause cold-like symptoms and may be linked to the development of T1D—in children with new-onset disease were presented by Knut Dahl-Jorgensen, M.D., Ph.D. Those who received the anti-viral medication maintained a higher level of insulin production after one year than those who did not take the medication, demonstrating that the treatment can slow the progression of T1D. The results were published in Nature Medicine.
- Heart Disease: In an EASD/Breakthrough T1D symposium, co-chaired by our own CEO Aaron Kowalski, Ph.D., presenters shared their insights on cardiovascular risk in youth with diabetes. Janet Snell-Bergeon, Ph.D., MPH, who has received a Breakthrough T1D grant to examine insulin resistance in T1D, spotlighted novel biomarkers for heart disease. The “ABCs” of diabetes risk factor management are HbA1c, blood pressure, and cholesterol levels, however, decreasing HbA1c, for example, is oftentimes not sufficient to reduce heart disease in T1D. To further stratify youth, APOC3 and GDF-15 proteins could be used as heart disease biomarkers. Ongoing research is integrating these into existing prediction models to verify their use as biomarkers for youth with T1D. If we can detect heart disease earlier, we can do earlier interventions, which can lead to the reversal of the early indicators of issues. In short, biomarkers let us see it earlier and act earlier.
- Also presenting on heart disease—which causes approximately three out of every four deaths in people with T1D—were members of the SFDT1 study, a Breakthrough T1D-funded research program that will follow 15,000 people with T1D over 30 years to better understand the factors associated with heart disease complications in T1D. This will offer new opportunities to better advance diabetes management, leading to more personalized prevention and improved quality of life.
- Stem Cell-Derived Therapy: In the summer of 2021, Vertex Pharmaceuticals launched its clinical trial of VX-880, a stem cell-derived islet replacement therapy in T1D for individuals with hypoglycemia unawareness, in combination with immunosuppressive therapy to protect the cells from rejection. To date, six participants have received this therapy, and three are now insulin independent. The phase I/II study is on Part C, where individuals receive a full dose of the therapy, and has opened multiple additional sites around the world.
- Once-Weekly Insulin: Novo Nordisk had results from its phase III ONWARDS 6 clinical trial, the first and only large study to date to investigate once-weekly insulin in people with T1D. There were 582 participants, and Novo Nordisk’s weekly insulin icodec was comparable to degludec (brand name Tresiba®), Novo Nordisk’s ultra-long-acting daily insulin. There was, however, a significantly higher rate of low blood sugar in people receiving icodec. Many participants noted, though, that they preferred once-weekly insulin over once-daily insulin, citing “frequency of injections” (70%) and “ease of use” (52%).
- Pregnancy + T1D: Most women with T1D struggle to reach the recommended blood-sugar targets when they are pregnant. But according to a new study presented by Helen Murphy, M.D., FRACP, an artificial pancreas system helped to substantially reduce maternal blood sugars throughout pregnancy. Published in The New England Journal of Medicine, the study authors say that—as a result of these findings—this technology should now be offered to all pregnant women with T1D to help improve maternal blood sugars.
- And, finally, congratulations to Breakthrough T1D-funded investigators:
-
- Åke Lernmark, M.D., Ph.D., received the 55th Claude Bernhard Medal, the highest award in recognition of contributions to the advancement of knowledge in the field of diabetes, for his role in dissecting the genetic and environmental causes of T1D;
- Yuval Dor, Ph.D., received the 17th Albert Renold Prize, given for a member’s outstanding achievement in research on the islets and their relationship to diabetes; and
- Roman Hovorka, Ph.D., received the EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, which awards an internationally recognized researcher who has contributed significantly to advances in the understanding, prevention, and treatment of diabetes and its complications. Dr. Hovorka has been at the forefront of artificial pancreas research, developing the algorithm in CamAPS® FX, which is now available in 16 countries and is used by over 16,000 people.
The next conference we’ll be covering is the International Society for Pediatric and Adolescent Diabetes (ISPAD) 49th Annual Conference, from October 18-21 in Rotterdam, The Netherlands. Stay tuned for a precap and recap of this terrific meeting!
Leading researchers from around the world will gather for the annual meeting of the European Association for the Study of Diabetes (EASD). At this year’s meeting, which will take place from October 2-6 in Hamburg, Germany, 65 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today.
EASD Highlights
- The first findings from the JDRF-funded clinical trial to test two anti-viral drugs against enteroviruses—a common virus that causes cold-like symptoms and may be linked to the development of T1D—in children with new-onset disease, presented by Knut Dahl-Jorgensen, M.D., Ph.D.
- Vertex Pharmaceuticals will present an update on the cell replacement therapy VX-880. We learned at the American Diabetes Association conference in June that six people had been treated, with two achieving insulin independence. We’re excited to hear more information on this groundbreaking trial!
- Chairing a session is our own CEO Aaron Kowalski, Ph.D., on a very important topic—heart disease in T1D youth and how to best detect it before children reach adulthood.
- And, finally, congratulations to Breakthrough T1D-funded investigators:
-
- Åke Lernmark, M.D., Ph.D., who will receive the 55th Claude Bernhard Medal, the highest award in recognition of contributions to the advancement of knowledge in the field of diabetes, for his role in dissecting the genetic and environmental causes of T1D;
- Yuval Dor, Ph.D., who will receive the 17th Albert Renold Prize, given for a member’s outstanding achievement in research on the islets and their relationship to diabetes; and
- Roman Hovorka, Ph.D., who will receive the EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, which awards an internationally recognized researcher who has contributed significantly to advances in the understanding, prevention, and treatment of diabetes and its complications.
The Albert Renold Prize has been given out annually since 2007. A total of 15 recipients have received Breakthrough T1D funding prior to winning the prize, including six investigators who received Breakthrough T1D early-career scientist grants. (Dr. Dor was a Breakthrough T1D postdoctoral fellow from 2003-2005 and a Breakthrough T1D Career Development Award from 2005-2010 and has received many more awards since.)
Stay Updated
Keep up with the latest updates and exciting news from the EASD Conference on Facebook (@myJDRF), X (formerly Twitter) (@JDRF), and LinkedIn, with the hashtags #JDRFxEASD and #EASD2023.
Each year, the Association of Diabetes Care & Education Specialists (ADCES) meeting brings together clinicians, researchers, and industry leaders together to address key issues affecting people with diabetes. This year, the meeting took place in Houston, Texas, from August 4-7, 2023.
Meeting sessions focused on the latest advancements in technology, self-care behaviors, program management skills, and clinical therapeutic approaches, and this year featured presentations from Sanjoy Dutta, Ph.D., chief scientific officer at Breakthrough T1D, and Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES, Breakthrough T1D’s director of community screening and clinical trials education.
Here are a few highlights:
- Dr. Dutta gave an update on the key initiatives in type 1 diabetes (T1D) research, stating, “The only metric of success is people with diabetes doing better. Otherwise, we haven’t done our job.” He described several developments that are “paradigm-shifting,” and outlined the focus of Breakthrough T1D research over the next five years:
-
- Developing and executing a global universal screening strategy that reduces diabetic ketoacidosis (DKA) at diagnosis
- Accelerating the development of disease-modifying therapies that delay, stop, or reverse the development and progression of T1D
- Advancing the development of first-generation stem cell-derived (and other sources of) beta cell replacement therapies
- Improving overall outcomes in people with T1D, to reduce disease burden and complications and barriers to the adoption of newly approved life-changing breakthroughs
- Dr. Albanese-O’Neill, who last year received the ADCES 2023 Diabetes Care and Education Specialist of the Year Award, received another honor: The prestigious Innovative Use of Technology Award, for her work at the University of Florida to develop the Knowledge Assessment of Type 1 Diabetes (KAT-1) tool that assesses peoples’ and/or their caregivers’ diabetes management knowledge prior to their clinic visit. In her presentation, she said the key to the future of diabetes care is individualized education and the integration of technology into clinic workflows, which KAT-1 is designed to do.
Diabetic ketoacidosis (DKA) is a life-threatening condition due to the shortage of insulin, causing symptoms such as dehydration, nausea and vomiting, confusion, difficulty breathing, and—if not caught early—death. Approximately one-third of people in the U.S. present with DKA at the time of T1D diagnosis.
- Katherine Barnard-Kelly, Ph.D., a former Breakthrough T1D-funded co-investigator, presented on person-reported outcomes (PROs), which the FDA defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else.” Dr. Barnard-Kelly and colleagues developed a consensus statement on the standardization of PROs, and her presentation focused on alleviating health inequities in diabetes through the integration of PROs into policy and research. She emphasized that the views and lived experiences of people with diabetes are essential to address inequalities in research and clinical practice, which Breakthrough T1D fully and unquestionably supports.
- In another talk on health inequity, Gregory Forlenza, M.D., a Breakthrough T1D-funded early-career scientist awardee, discussed how the MiniMed 780G, an artificial pancreas system, democratizes diabetes management. Using data from a clinical study evaluating the impact of MiniMed 780G in high-risk youth, the study found that they achieved a 9.3 hour per day increase in time-in-range, from 28% to 67%, and an average reduction in HbA1c, going from 10.5% to 7.6%. These data, said Dr. Forlenza, demonstrate that those who would not be considered “ideal” candidates due to their high HbA1c are the people who stand to benefit the most from this technology.
The American Diabetes Association’s 83rd Scientific Sessions is here! Scientists will present the latest type 1 diabetes (T1D) research, from beta cell replacement to regeneration, and glucose and complications trials, all with the goal of improving lives for the T1D community.
Here are Breakthrough T1D-funded researchers Drs. Sarit Polsky, Riitta Veijola, Maria Golson, and Patrice Fort to share their key takeaways from day 3, with their commentary in the video and below:
Sarit Polsky, M.D., MPH
Director, Pregnancy and Women’s Health Clinic, Barbara Davis Center for Diabetes, University of Colorado
Area: Automated Insulin Delivery Use among Pregnant Women with Type 1 Diabetes—Past, Present, and Future
Managing T1D with pregnancy is difficult, and artificial pancreas, or automated insulin delivery (AID), systems—for the most part—are not tailored to pregnancy. There are significant changes to insulin requirements over the course of pregnancy, making it difficult for pregnant women to achieve blood-sugar targets. Continuous glucose monitors (CGMs) help women increase their time spent in the optimal, pregnancy-specific time-in-range, but even with CGM some pregnant individuals do not reach their targets until the last few weeks of pregnancy.
Presenting on AID systems in pregnancy were Helen Murphy, M.D., FRACP, Carol Levy, M.D., CDCES, Sarit Polsky, M.D., MPH, and Denise Feig, M.D., M.Sc., FRCPC. They discussed the commercially available system for pregnancy (CAM APS, the only available system for pregnant women), “off-label” AID systems (like Medtronic, Tandem, Insulet, and iLet—which are not approved for pregnancy), and those in clinical trials, including one that has a special pregnancy-specific algorithm, developed by Harvard researcher (and Breakthrough T1D-funded) Eyal Dassau, Ph.D.
There are still a lot of things in the future we have to figure out—What is the optimal time-in-range? Should it be different overnight or during the day? What are the barriers to automation, such as cost and skin issues? There are currently five studies underway, with results that will be published in the next year or two.
“We’ve made a lot of progress and it’s all very exciting,” says Dr. Polsky, “so we all have a lot to look forward to.”
Riitta Veijola, M.D., Ph.D.
University of Oulu
Area: Joint ADA/Breakthrough T1D Symposium—Global Perspective on Population Level Type 1 Diabetes Screening and Monitoring
Anette-Gabriele Ziegler, M.D., Cristy Geno Rasmussen, MPH, Ph.D., and Riitta Veijola, M.D., Ph.D., presented on global screening in Europe and the United States, in a session run by Breakthrough T1D’s own Sanjoy Dutta, Ph.D., chief scientific officer at Breakthrough T1D. Dr. Veijola, who has been working on the development of T1D in children for almost 30 years, summarized the screening process. In Finland—the country with the highest rate of T1D—the most common age when islet autoantibodies appear is around 1 year, for reasons that are being explored in current studies.
2+ autoantibodies—antibodies that are directed toward your own body—means you have an almost 100 percent chance of developing T1D in your lifetime.
A screening test can tell you if you have 2+ autoantibodies. If you do, blood-sugar levels need to be monitored for the onset of type 1. You can do this in multiple ways. The traditional way is a glucometer with strips. A more modern way is continuous glucose monitoring (CGM) technology, which gives you your blood-sugar levels every 5 minutes. Another measure is to test HbA1c, which can tell you about blood-sugar levels over the past 12 weeks.
Monitoring can help you avoid diabetic ketoacidosis (DKA)—a complication of T1D when there is too much blood sugar, that can lead to death if not caught early. Monitoring also gives you time to learn about T1D and an opportunity to take part in preventive treatment, like Tzield™ (teplizumab-mzwv), or a clinical trial. To learn more about screening and monitoring, go to our T1Detect program.
Maria L. Golson, Ph.D.
Assistant Professor, Johns Hopkins School of Medicine
Area: The Islet-Cell Interactome
Alpha cells! Beta cells! Delta cells! Oh my! Maria Golson, Ph.D., and the presenters in her session, Manami Hara, DDS, Ph.D., Danielle Dean, Ph.D., and Abdelfattah El Ouaamari, Ph.D., talked about the other cells and blood vessel architecture in T1D, and how they contribute to beta cell failure.
Dr. Golson presented on delta cells, which produce somatostatin, a hormone that inhibits insulin secretion and is also released in response to high glucose as the hormone helps regulate the gastrointestinal tract. Next up was Dr. Hara, who talked about the blood vessel system in the islets, who demonstrated that there’s more interaction than previously thought between the blood vessel tissue and islet tissue. Dr. Dean spoke about glucagon, which is secreted by the alpha cell, which is also important for regulating insulin secretion. Finally, Dr. El Ouaamari found that islets have different sensory neurons, which might explain some of the differences in diabetes incidence in males and females.
Islets were previously thought to be made up of different cells, each responsible for a singular function. Now, we see that these different cells communicate with and among each other. Additional study of these interactions could help illuminate a path to new research and therapies that act upon these intercellular actions.
Patrice Fort, M.S., Ph.D.
Associate Professor and Director, Biorepository and Resource Center, University of Michigan
Area: Creating a World without Visual Loss from Diabetes
Patrice Fort, M.S., Ph.D., presented on the Mary Tyler Moore Vision Initiative (MTM Vision), with S. Robert Levine, M.D., the husband of the late Mary Tyler Moore and creator of MTM Vision, and Jennifer Sun, M.D., MPH. The first part of this initiative, due to a workshop hosted by Breakthrough T1D in 2018, is a new Diabetic Retinal Disease Staging System, to update the grading system that has not been changed for 50 years, despite the advancement of our understanding the disease and its presentation. An article outlining the new Diabetic Retinal Disease Staging System is set for publication in the coming months.
The workshop also detailed the state of the science, and outlined scientific needs and opportunities, which helped establish a “roadmap” for next steps.
One of these, presented by Dr. Fort, is collecting and characterizing different stages of the disease, to do a very in-depth analysis of those tissues to identify new potential targets to be developed with pharma companies or other academic centers. Another one, presented by Dr. Sun, is new clinical endpoints and biomarkers for better characterization of the progression of the disease. She is spearheading clinical trials that will take place at the beginning of next year.
MTM Vision’s goal is to lead to the development of therapies that will reduce or reverse vision-threatening diabetic eye disease development and progression. Ultimately, it aims to create a world without visual loss from diabetes, honoring Mary Tyler Moore’s commitment to diabetes awareness and research.
The American Diabetes Association’s 83rd Scientific Sessions is here! Until June 26, scientists will present the latest type 1 diabetes (T1D) research, from beta cell replacement to regeneration, and glucose and complications trials, all with the goal of improving lives for the T1D community.
Here are Breakthrough T1D-funded researchers Drs. Martin Thelin and Robert Eckel to share their key takeaways from day 2, with their commentary in the video and below:
Martin Thelin, M.D., Ph.D.
Clinical Fellow–Pediatrics, University of California, San Francisco
Area: Type 1 Diabetes Through Another Lens—Lessons from Other Disease Settings
It has been known for some time that T1D is associated with increased risk of developing other autoimmune diseases, such as celiac disease, multiple sclerosis, and lupus. But cancer? It turns out that some patients on cancer immunotherapy go on to develop T1D. And there is a monogenic—meaning something that involves or is controlled by one gene—form of diabetes. It’s different from T1D or T2D, and while rare and requires a genetic test for accurate diagnosis, it can be studied for its relationship to T1D.
First up was Breakthrough T1D-funded Halis Akturk, M.D., who presented on checkpoint inhibitors—drugs that take the brakes off the immune system—in cancer and how they may lead to T1D. Next up was Martin Thelin, M.D., Ph.D., who has a Breakthrough T1D advanced postdoctoral fellowship in the laboratory of Dr. Mark Anderson, presenting on monogenic diabetes and how it can teach us about T1D. Lastly, there was Edwin Liu, M.D., who presented on celiac disease and how it correlates with T1D.
This session shone a light on how other diseases can be a resource for better understanding and managing T1D.
Robert H. Eckel, M.D.
Professor Emeritus, University of Colorado Anschutz Medical Campus
Area: Implementation of Guideline-Directed Medical Therapy for Cardiometabolic Disease—Emerging Multidisciplinary Initiatives
While he was at the University of Washington in Seattle from 1977 to 1979, Robert Eckel, M.D., was one of the first Breakthrough T1D-funded postdoctoral fellows. Now at the University of Colorado, he has been president of both the American Diabetes Association and the American Heart Association and has gone on to be an expert in cardiometabolic disorders. Cardiometabolic disorders are a cluster of interrelated factors, including high blood pressure, elevated blood-sugar levels, and high cholesterol, that put someone at high risk for having a heart attack or a stroke. Dr. Eckel also has type 1 diabetes and has had it for more than 70 years.
In Dr. Eckel’s video, he talks about a clinical trial for type 2 diabetes, in which participants had bariatric surgery (surgery intended to help a person lose weight) and were followed for 12 years to see how many people went into remission. In the beginning, the participants lost weight and there was also some remission of type 2 diabetes, which is defined by an HbA1c of under 6.5% and being off diabetes-related medicines. At one year, 50% of participants had a remission of type 2 diabetes. At 12 years, however, most of them—80%—had type 2 diabetes again.
“What are the predictors of poor outcomes?” Dr. Eckel posed. “I turned to the historical literature here. It’s people who have longer durations of diabetes and also people who are on more medications to treat their diabetes.”
This has relevance for type 1 diabetes, as longer durations of diabetes often lead to an HbA1c that is 7% or higher and may lead to complications that require diabetes-related medicines, similar to type 2. Research on these metabolic measures will ultimately benefit all of those in the diabetes space, whether it’s type 2 or type 1.